Figure 3 | Scientific Reports

Figure 3

From: The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis

Figure 3

(A) OS of EGFR-TKI plus bevacizumab and EGFR-TKI monotherapy by the baseline status of brain metastasis (B) Cumulative incidence of systemic progression without death (red) and CNS progression alone without death (black) between EGFR-TKI plus bevacizumab and EGFR-TKI monotherapy groups in patients with baseline brain metastasis. bev bevacizumab, BM brain metastasis, TKI tyrosin kinase inhibitor.

Back to article page